Pharma Mar, S.A. (BME:PHM)

Inozyme Pharma Statistics

Total Valuation

Pharma Mar has a market cap or net worth of EUR 1.39 billion. The enterprise value is 1.31 billion.

Market Cap	1.39B
Enterprise Value	1.31B

Important Dates

The last earnings date was Friday, July 25, 2025.

Earnings Date	Jul 25, 2025
Ex-Dividend Date	Jun 25, 2025

Share Statistics

Pharma Mar has 17.57 million shares outstanding.

Current Share Class	17.57M
Shares Outstanding	17.57M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	11.79%
Owned by Institutions (%)	9.65%
Float	12.74M

Valuation Ratios

The trailing PE ratio is 33.09 and the forward PE ratio is 20.70.

PE Ratio	33.09
Forward PE	20.70
PS Ratio	7.35
PB Ratio	6.90
P/TBV Ratio	6.94
P/FCF Ratio	782.76
P/OCF Ratio	157.97
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 34.52, with an EV/FCF ratio of 739.58.

EV / Earnings	31.27
EV / Sales	6.94
EV / EBITDA	34.52
EV / EBIT	41.78
EV / FCF	739.58

Financial Position

The company has a current ratio of 2.84, with a Debt / Equity ratio of 0.26.

Current Ratio	2.84
Quick Ratio	2.14
Debt / Equity	0.26
Debt / EBITDA	1.35
Debt / FCF	28.94
Interest Coverage	7.69

Financial Efficiency

Return on equity (ROE) is 21.94% and return on invested capital (ROIC) is 8.30%.

Return on Equity (ROE)	21.94%
Return on Assets (ROA)	5.91%
Return on Invested Capital (ROIC)	8.30%
Return on Capital Employed (ROCE)	12.07%
Revenue Per Employee	378,534
Profits Per Employee	84,018
Employee Count	500
Asset Turnover	0.57
Inventory Turnover	0.19

Taxes

Income Tax	-9.13M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +118.63% in the last 52 weeks. The beta is -0.11, so Pharma Mar's price volatility has been lower than the market average.

Beta (5Y)	-0.11
52-Week Price Change	+118.63%
50-Day Moving Average	81.94
200-Day Moving Average	81.95
Relative Strength Index (RSI)	45.92
Average Volume (20 Days)	45,772

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharma Mar had revenue of EUR 189.27 million and earned 42.01 million in profits.

Revenue	189.27M
Gross Profit	179.76M
Operating Income	31.44M
Pretax Income	32.88M
Net Income	42.01M
EBITDA	35.93M
EBIT	31.44M
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 128.08 million in cash and 51.40 million in debt, giving a net cash position of 76.68 million or 4.36 per share.

Cash & Cash Equivalents	128.08M
Total Debt	51.40M
Net Cash	76.68M
Net Cash Per Share	4.36
Equity (Book Value)	201.53M
Book Value Per Share	n/a
Working Capital	161.62M

Cash Flow

In the last 12 months, operating cash flow was 8.80 million and capital expenditures -7.02 million, giving a free cash flow of 1.78 million.

Operating Cash Flow	8.80M
Capital Expenditures	-7.02M
Free Cash Flow	1.78M
FCF Per Share	0.10

Margins

Gross margin is 94.98%, with operating and profit margins of 16.61% and 22.20%.

Gross Margin	94.98%
Operating Margin	16.61%
Pretax Margin	17.37%
Profit Margin	22.20%
EBITDA Margin	18.98%
EBIT Margin	16.61%
FCF Margin	0.94%

Dividends & Yields

This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 1.01%.

Dividend Per Share	0.80
Dividend Yield	1.01%
Dividend Growth (YoY)	23.08%
Years of Dividend Growth	1
Payout Ratio	33.20%
Buyback Yield	n/a
Shareholder Yield	1.01%
Earnings Yield	3.02%
FCF Yield	0.13%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 22, 2020. It was a reverse split with a ratio of 0.0833333333.

Last Split Date	Jul 22, 2020
Split Type	Reverse
Split Ratio	0.0833333333

Scores

Pharma Mar has an Altman Z-Score of 7.13 and a Piotroski F-Score of 6.

Altman Z-Score	7.13
Piotroski F-Score	6